ReviewBiomarker insights2019
Blood Biomarkers of Parenchymal Damage in Ischemic Stroke Patients Treated With Revascularization Therapies.
Review in Biomarker insights, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07422636 (Integrating Novel NeuroImaging Measurements and Circulating Biomarkers for the Prediction of Secondary Injury foLlowing strokE), which is not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integrating Novel NeuroImaging Measurements and Circulating Biomarkers for the Prediction of Secondary Injury foLlowing strokE: From Bench to Bedside - The NIMBLE Study (NIMBLE)
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- High-Resolution Spatiotemporal Mapping of Cerebral Metabolism During Middle-Cerebral-Artery Occlusion/Reperfusion Progression: Preliminary Insights.Biomolecules · 2025Article
- A novel model of light-induced middle cerebral artery occlusion and recanalization in mice.Communications biology · 2025Article
- Predicting reperfusion injury and functional status after stroke using blood biomarkers: the STROKELABED study.Journal of translational medicine · 2025Article
- Evaluating predictive models for hemorrhagic transformation post-mechanical thrombectomy in acute ischemic stroke.Frontiers in neurology · 2025Review
- Hemorrhagic Transformation in Ischemic Stroke and the Role of Inflammation.Frontiers in neurology · 2021Review
- Metabolome Changes in Cerebral Ischemia.Cells · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePostischemic reperfusion injury may exacerbate cerebral damage and capillary dysfunction, leading to brain edema (BE), hemorrhagic transformation (HT), necrosis, and injury from free radicals with subsequent infarct growth (IG). Several plasmatic biomarkers involved in the ischemic cascade have been studied in relation to radiological and clinical outcomes of reperfusion injury in ischemic stroke with heterogeneous results. This article provides a brief overview of the contribution of circulating biomarkers to the pathophysiology of parenchymal damage in ischemic stroke patients treated with revascularization therapies.
methodsWe included full reports with measurements of plasma markers in patients with acute ischemic stroke treated with revascularization therapies.
findingsOur research included a large number of observational studies investigating a possible role of circulating biomarkers in the development of parenchymal damage after acute stroke treatments. To make the results clearer, we divided the review in 4 sections, exploring the relation of different biomarkers with each of the indicators of parenchymal damage (HT, BE, IG, recanalization). DISCUSSION AND
conclusionDefinite conclusions are difficult to draw because of heterogeneity across studies. However, our review seems to confirm an association between some circulating biomarkers (particularly matrix metalloproteinase-9) and occurrence of parenchymal damage in ischemic stroke patients treated with revascularization therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.